摘要
目的 :探讨拉米夫定治疗慢性乙型重型病毒性肝炎的疗效和安全性。方法 :86例慢性乙型重型病毒性肝炎分为两组。对照组 3 8例 ,给予常规内科综合治疗 ;拉米夫定组 48例 ,在综合治疗的基础上 ,加用拉米夫定。统计两组的病死率、存活者肝功能恢复情况及平均住院时间。结果 :治疗组患者病死率为 41 7% ,对照组为 68 4% ,两组患者病死率经统计学处理差异有显著性意义 (P <0 0 5 ) ;治疗组存活者达到显效出院平均住院时间为 (74 6±2 2 7)天 ,明显短于对照组的 (114 3± 2 6 2 )天 (P <0 0 5 )。拉米夫定治疗期间未见明显副反应 ,显示良好的安全性。结论 :拉米夫定治疗慢性乙型重型病毒性肝炎是有效和安全的 ,可作为抢救重型乙型肝炎的治疗药物之一。
Objective:To evaluate the efficacy and safety of Lamivudine in the treatment of chronic severe hepatitis due to hepatitis B virus (HBV). Methods:Eighty-six patients with chronic severe hepatitis caused by HBV were randomly allocated into two groups. Control group (n=38) was given conventional therapy;Lamivudine group(n=48) was treated with Lamivudine, 100mg daily on the basis of routine management. The mortality rate and hospital stay duration of two groups were analyzed. Results:The mortality rate of Lamivudine group was 41.7%. The mortality rate of control group was 68.4%. There was significant difference in mortality between the two groups( P <0.05). The mean hospital stay duration of control group was greatly longer than that of Lamivudine group[(114.3±26.2) days vs.(74.6±22.7) days, P <0.05].No remarkable adverse effects of Lamivudine were observed.Conclusions:Lamivudine may be effective and safe in the treatment of chronic severe hepatitis due to exacerbation of chronic hepatitis B.
出处
《中西医结合肝病杂志》
CAS
2004年第5期264-266,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
深圳市科技局科研基金 (No:2 0 0 0 0 0 4 0 60 )
